NL238796A - - Google Patents

Info

Publication number
NL238796A
NL238796A NL238796DA NL238796A NL 238796 A NL238796 A NL 238796A NL 238796D A NL238796D A NL 238796DA NL 238796 A NL238796 A NL 238796A
Authority
NL
Netherlands
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication of NL238796A publication Critical patent/NL238796A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NL238796D 1958-05-07 NL238796A (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DEF25702A DE1111642B (de) 1958-05-07 1958-05-07 Verfahren zur Herstellung von basisch substituierten Diphenylmethan-Derivaten mit Herz- und Kreislaufwirksamkeit

Publications (1)

Publication Number Publication Date
NL238796A true NL238796A (en:Method)

Family

ID=7091732

Family Applications (2)

Application Number Title Priority Date Filing Date
NL108640D NL108640C (en:Method) 1958-05-07
NL238796D NL238796A (en:Method) 1958-05-07

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NL108640D NL108640C (en:Method) 1958-05-07

Country Status (10)

Country Link
US (1) US3152173A (en:Method)
BE (1) BE578515A (en:Method)
CH (8) CH397710A (en:Method)
CY (1) CY277A (en:Method)
DE (1) DE1111642B (en:Method)
FR (1) FR553M (en:Method)
GB (1) GB916644A (en:Method)
MY (1) MY6400049A (en:Method)
NL (2) NL238796A (en:Method)
OA (1) OA01363A (en:Method)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3262977A (en) * 1962-03-10 1966-07-26 Chinoin Gyogyszer Es Vegyeszet N-aralkyl-1, 1-diphenyl-propylamine derivatives
NL296693A (en:Method) * 1962-08-16
DK111894A (en:Method) 1962-11-15
FR95908E (fr) * 1963-11-09 1972-01-31 Degussa Procédé de préparation de nouvelles aminocétones et des alcools secondaires correspondants.
DE1231704B (de) 1963-12-19 1967-01-05 Josef Klosa Dipl Chem Dr Rer N Verfahren zur Herstellung neuer Diaryl-alkylaminoverbindungen mit heterocyclischen Ringen
US3457354A (en) * 1965-09-21 1969-07-22 Merck & Co Inc Treatment of hypertension with 2-hydroxy (or amino) - 4,5 - dihydroxyphenethylamine derivatives
US3895057A (en) * 1967-10-13 1975-07-15 Dainippon Pharmaceutical Co Aminoalkanols and their pharmaceutically acceptable acid-addition salts, and production thereof
US4329367A (en) * 1974-08-05 1982-05-11 Ciba-Geigy Corporation 1-(Aralkoxyphenyl)-2-(bis-arylalkylamino)-alkanes
DE2902172C2 (de) * 1979-01-20 1984-05-10 UOP Inc., 60016 Des Plaines, Ill. Verfahren zur Herstellung eines N,N'-Dialkylphenylendiamins
JPS59500764A (ja) * 1982-04-23 1984-05-04 カオラ　コズメテイカイ　エス　ハズタルタスベジパリ　バララト プレニルアミン含有化粧品組成物
NZ215753A (en) * 1985-04-16 1989-10-27 Hoffmann La Roche Phenethanolamine derivatives and pharmaceutical compositions
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1671650A1 (en) * 2001-01-26 2006-06-21 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
AU2002237927B2 (en) * 2001-01-26 2005-04-21 Schering Corporation Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
AR035739A1 (es) * 2001-01-26 2004-07-07 Schering Corp Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares
ES2286233T3 (es) * 2001-01-26 2007-12-01 Schering Corporation Combinaciones de inhibidor(es) de la absorcion de esteroles con agente(s) cardiovascular(es) para el tratamiento de afecciones vasculares.
ATE348649T1 (de) * 2001-01-26 2007-01-15 Schering Corp Kombinationen von einem hemmer der sterol- absorption und einem ppar-aktivator zur behandlung von kardiovaskulären indikationen
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
PL205343B1 (pl) * 2001-01-26 2010-04-30 Schering Corp Zastosowanie inhibitora wchłaniania sterolu
AU2002308778A1 (en) * 2001-05-25 2002-12-09 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
EP1427409B1 (en) * 2001-09-21 2008-10-15 Schering Corporation Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
CA2460340C (en) * 2001-09-21 2011-02-15 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
EP1545519B1 (en) 2002-08-19 2011-03-23 Pfizer Inc. Combination therapy for hyperproliferative diseases
CA2504878A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
ES2318274T3 (es) 2003-03-07 2009-05-01 Schering Corporation Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
US7192944B2 (en) * 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2007510659A (ja) * 2003-11-05 2007-04-26 シェーリング　コーポレイション 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
AU2005269465A1 (en) * 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
EP1951253A2 (en) 2005-10-26 2008-08-06 Cotherix, Inc. Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
EP2094643B1 (en) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8883844B2 (en) 2010-09-24 2014-11-11 Nitrogenix Inc. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
ES3007652T3 (en) 2019-01-18 2025-03-20 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluoromethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-one as pcsk9 inhibitor and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2601323A (en) * 1949-02-02 1952-06-24 Upjohn Co Process for preparing 4, 4-diphenyl-6-dimethylamino-heptanone-3
US2681934A (en) * 1950-01-06 1954-06-22 Commercial Solvents Corp Substituted diphenylalkylamines
US2797242A (en) * 1953-08-11 1957-06-25 Parke Davis & Co Substituted alpha-benzylphenethylamines and methods for producing the same
US2738347A (en) * 1954-12-13 1956-03-13 Olin Mathieson Penicillin salt of benzhydryl-phenethylamine
US2872374A (en) * 1955-02-02 1959-02-03 Nat Drug Co Muscle-relaxing tranquilizer compositions
US2894033A (en) * 1955-11-15 1959-07-07 Nl Combinatie Chem Ind Antispasmodic 1, 1-diphenyl-3-dialkylaminopropane, and its tertiary and quaternary salts
US2854379A (en) * 1956-06-06 1958-09-30 Miles Lab Tranquilizing composition comprising 2-ethyl-cis-crotonylurea
DE1058063B (de) * 1957-02-08 1959-05-27 Hoechst Ag Verfahren zur Herstellung von analgetisch wirksamen substituierten Phenylaethylaminen

Also Published As

Publication number Publication date
CH397710A (de) 1965-08-31
CY277A (en) 1964-02-12
CH388328A (de) 1965-02-28
CH388332A (de) 1965-02-28
DE1111642B (de) 1961-07-27
US3152173A (en) 1964-10-06
MY6400049A (en) 1964-12-31
GB916644A (en) 1963-01-23
FR553M (en:Method) 1961-05-29
CH388329A (de) 1965-02-28
OA01363A (fr) 1969-07-04
BE578515A (en:Method)
NL108640C (en:Method)
CH396931A (de) 1965-08-15
CH385878A (de) 1964-12-31
CH388333A (de) 1965-02-28
CH388334A (de) 1965-02-28

Similar Documents

Publication Publication Date Title
FR553M (en:Method)
AT214638B (en:Method)
AT221043B (en:Method)
AT217439B (en:Method)
AT215747B (en:Method)
AT213316B (en:Method)
AT213446B (en:Method)
AT216227B (en:Method)
AT215751B (en:Method)
AT213908B (en:Method)
AT219815B (en:Method)
AT214348B (en:Method)
AT214270B (en:Method)
AT215738B (en:Method)
AT213670B (en:Method)
AT213631B (en:Method)
AT213558B (en:Method)
AT216612B (en:Method)
AT216749B (en:Method)
AT216771B (en:Method)
AT216803B (en:Method)
AT216831B (en:Method)
AT213557B (en:Method)
AT217982B (en:Method)
AT213472B (en:Method)